ÂÜÀòÂÒÂ×

Shyanne Ali has extensive experience in the pharmaceutical and biotechnology industries. Shyanne is currently working as the Vice President of Quality Assurance at Aditum Bio since April 2022. Prior to this, they held the position of Head of R&D Quality at Intercept Pharmaceuticals from March 2020 to October 2020.

Shyanne also served as the Head of Quality Assurance at TrialSpark from November 2018 to March 2020. Before that, they worked at Boehringer Ingelheim as the US Head of Quality Management Medicine (Executive Director) from May 2016 to November 2018.

Their previous roles include being the Global Standards Compliance Governance Office Director- Global Compliance at Novartis Oncology from February 2015 to April 2016, and Head of GMO Compliance- Clinical Development at Novartis Vaccines from September 2013 to February 2015.

Shyanne started their career at Novartis Oncology as a Senior Clinical Trial Head in March 2009, where they provided scientific and operational leadership in managing breast cancer registration trials. Shyanne was responsible for process improvement initiatives and regularly presented best practices across the oncology division.

Before Novartis, they worked as a Clinical Research Manager at Abbott Laboratories from March 2004 to February 2009. Shyanne began their career in the pharmaceutical industry as a Senior Clinical Research Associate at various Clinical Research Organizations from September 2001 to February 2004.

Shyanne Ali's education history includes attending Montclair State University and Temple University. However, no specific details are provided regarding the start and end years, degree names, or fields of study for either institution.